Invasive and in situ cervical cancer reported to the vaccine adverse event reporting system (VAERS)

Journal of Women's Health

Volumn 19, Issue 3, 2010, Pages 365-370

  Wong, Charlene ^a   Krashin, Jamie ^b   Rue Cover, Alison ^c   Saraiya, Mona ^a   Unger, Elizabeth ^d   Calugar, Angela ^c   Markowitz, Lauri ^b  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL CENTER FOR PREPAREDNESS DETECTION AND CONTROL OF INFECTIOUS DISEASES   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ARTICLE; CANCER INVASION; CANCER SCREENING; CANCER STAGING; DATA BASE; DIAGNOSTIC TEST; FEMALE; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; SCREENING TEST; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; VACCINE ADVERSE EVENT REPORTING SYSTEM;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77950222640     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2009.1891     Document Type: Article

References (37)

1. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007;56(RR-1):1-24.
2. U.S. Food and Drug Administration. FDA approves new vaccine for prevention of cervical cancer [press release]. October 16, 2009. Available at www.fda.gov=NewsEvents= Newsroom=PressAnnouncements=ucm187048.htm Accessed November 19, 2009.
3. Eckert L, LaMontagne D, Jumaan A, Hombach J. HPV vaccine implementation in middle and low income countries [abstract]. 25th International Papillomavirus Conference, May 8-14, 2009, Malmo, Sweden. Available at www. hpv2009.org=Abstractbok-hela%20webb%20low[1].pdf Accessed November 19, 2009.
4. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369: 2161-2170.
5. Ault KA, FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomised clinical trials. Lancet 2007;369:1861-1868.
6. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927.
7. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-1943.
8. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16=18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial. JAMA 2007;298:743-753.
9. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297:813-819.
10. Dillner J, Arbyn M, Dillner L. Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination. Clin Exp Immunol 2007;148:199-207.
11. Howlett RI, Miller AB, Pasut G, Mai V. Defining a strategy to evaluate cervical cancer prevention and early detection in the era of HPV vaccination. Prev Med 2009;48:432-437.
12. Stanley M, Villa LL. Monitoring HPV vaccination. Vaccine 2008;26(Suppl 1):A24-27.
13. Dunne EF, Datta SD, Markowitz LE. A review of prophylactic human papillomavirus vaccines: Recommendations and monitoring in the U.S. Cancer 2008;113:2995-3003.
14. Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. MMWR 2003; 52:SS1-24. Available at www.cdc.gov=mmwr=preview= mmwrhtml=ss5201a1.htm Accessed November 19, 2009.
15. Varricchio F, Iskander J, Destefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004;23: 287-294.
16. Singleton JA, Lloyd JC, Mootrey GT, Salive ME, Chen RT, VAERS Working Group. An overview of the Vaccine Adverse Event Reporting System (VAERS) as a surveillance system. Vaccine 1999;17:2908-2917.
17. Food and Drug Administration. 21CFR Part 600.80. Postmarketing reporting of adverse experiences. Fed Register 1997;62:52-53.
18. Muñ oz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527.
19. Beller U, Abu-Rustum NR. Cervical cancers after human papillomavirus vaccination. Obstet Gynecol 2009;113: 550-552.
20. Clifford G, Franceschi S, Diaz M, Muñ oz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24(Suppl 3):S3=26-34.
21. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16=18 vaccine. J Natl Cancer Inst 2004;96:604-615.
22. Kahn JA, Burk RD. Papillomavirus vaccines in perspective. Lancet 2007;369:2135-2137.
23. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: A longitudinal cohort study. Lancet 2001;357:1831-1836.
24. Winer RL, Feng Q, Hughes JP, O'Reilly S, Kiviat NB, Koutsky LA. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 2008; 197:279-282.
25. Mosher WD, Chandra A, Jones J. Sexual behavior and selected health measures: Men and women 15-44 years of age, United States, 2002. Adv Data 2005;362:1-55.
26. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907.
27. Castle P. Cervical cancers after human papillomavirus vaccination. Obstet Gynecol 2009;114:174.
28. Joura EA, Garland SM. Cervical cancers after human papillomavirus vaccination. Obstet Gynecol 2009;114:174-175.
29. Iskander JK, Miller ER, Chen RT. The role of the Vaccine Adverse Event Reporting System (VAERS) in monitoring vaccine safety. Pediatr Ann 2004;33:599-606.
30. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001;344:564-572.
31. Goodman MJ, Nordin J. Vaccine Adverse Event Reporting System reporting source: A possible source of bias in longitudinal studies. Pediatrics 2006;117:387-390.
32. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: Terminology for reporting results of cervical cytology. JAMA 2002;287:2114-2119.
33. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer. J Lower Genit Tract Dis 2003;7: 67-86.
34. U.S. Preventive Services Task Force. Screening for cervical cancer: Recommendations and rationale 2003. Available at www.ahrq.gov=clinic=3rduspstf= cervcan=cervcanrr.pdf Accessed November 24, 2008.
35. ACOG Practice Bulletin No. 109: Cervical Cytology Screening. Obstet Gynecol 2009;114:1409-1420.
36. Saslow D, Castle PE, Cox JT, et al. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007;57:7-28.
37. Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008;26(Suppl 1):A16-23.